Menu Search
Equities

Oncosil Medical Ltd

OCMLF:PKC

Oncosil Medical Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded500.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 13:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

  • Revenue in AUD (TTM)583.20k
  • Net income in AUD-11.91m
  • Incorporated2005
  • Employees2.00
  • Location
    Oncosil Medical LtdLevel 57 Eden Park Drive, Macquarie ParkMACQUARIE 2113AustraliaAUS
  • Phone+61 28935-9629
  • Fax+61 29221-8535
  • Websitehttp://www.oncosil.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.